Data on safety and immunogenicity of Vaccitech’s flu vaccine have been presented at the 2018 Annual Conference on Vaccinology Research, run by the National Foundation for Infectious Diseases. The presentation was entitled:
A Clinical Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Novel Avian Cell Line, in Healthy Adult Volunteers.
Data were presented by Pedro M. Folegatti MD, of The Jenner Institute, University of Oxford, United Kingdom. The data were produced in a small study to explore safety and immunogenicity of the universal flu vaccine, which was manufactured in a continuous, defined cell line.
The vaccine was administered to 6 healthy volunteers, with no severe or serious adverse events reported. Immunogenicity was encouraging, with significantly higher levels of relevant T cells at day 21 compared with baseline. A comparison was also made between a trial using a vaccine lot produced in Chicken Embryo Fibroblasts and a lot manufactured in the AGE1.CR.pIX cell line, with post-vaccination T cell levels trending higher in the cell-manufactured vaccine.
Vaccitech is currently enrolling up to 3,200 patients in a global Phase 2b study that will complete in Q3 2019.